Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 21, Issue 11, Pages 1329-1336Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14656566.2020.1751124
Keywords
Central nervous system involvement; everolimus; mTOR inhibitor; rapamycin; sirolimus; therapy; treatment; tuberous sclerosis complex
Categories
Ask authors/readers for more resources
Introduction: Subependymal ependymal giant cell astrocytomas (SEGAs) occur almost exclusively in the setting of tuberous sclerosis (TSC). They are low-grade gliomas which typically produce clinical symptoms through either mass effect or hydrocephalus. As do other manifestations of tuberous sclerosis, these lesions result from mutations in either the TSC1 or the TSC2 gene. These mutations cause hyperactivation of the mechanistic target of rapamycin (mTOR). In view of their tendency to grow slowly, clinical symptoms usually only occur when the tumors reach a considerable size. Therapy can involve surgical resection, cerebrospinal fluid diversion, or medical therapy with an mTOR inhibitor. Areas covered: Herein, the authors discuss the diagnosis, symptoms, and practical management of SEGAs as well as providing their expert opinion. Expert opinion: mTOR inhibitors have largely replaced surgery as the primary modality for the management of SEGAs. Surgical treatment is largely limited to tumors that present with acute hydrocephalus and increased intracranial pressure. Patients with TSC should undergo periodic screening with CT or preferably MRI scans of the brain from childhood to approximately age 25 to identify SEGAs which require treatment. In addition to avoiding potential morbidity associated with surgical resection, mTOR inhibitors have the potential to improve the clinical status of tuberous sclerosis patients generally.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available